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ABSTRACT 
Background: Despite recommendations, people with heart failure have poor access to 
palliative care.  
Aim: To identify the evidence in relation to palliative care for people with symptomatic heart 
failure.  
Design: Systematic review and narrative synthesis. (PROSPERO CRD42016029911)  
Data sources: Databases (Medline, Cochrane database, CINAHL, PsycINFO, HMIC, 
CareSearch Grey Literature), reference lists and citations were searched and experts 
contacted. Two independent reviewers screened titles, abstracts and retrieved papers against 
inclusion criteria. Data were extracted from included papers and studies were critically 
assessed using a risk of bias tool according to design.  
Results: Thirteen interventional and ten observational studies were included. Studies were 
heterogeneous in terms of population, intervention, comparator, outcomes, and design 
rendering combination inappropriate. The evaluation phase studies, with lower risk of bias, 
using a multi-disciplinary specialist palliative care intervention showed statistically 
significant benefit for patient-reported outcomes (symptom burden, depression, functional 
status, quality of life), resource use and costs of care. Benefit was not seen in studies with a 
single component/discipline intervention or with higher risk of bias. Possible contamination 
in some studies may have caused under-estimation of effect and missing data may have 
introduced bias. There was no apparent effect on survival.  
Conclusions: Overall, the results support the use of multi-disciplinary palliative care in 
people with advanced heart failure but trials do not identify who would benefit most from 
specialist palliative referral. There are no sufficiently robust multi-centre evaluation phase 
trials to provide generalisable findings. Use of common population, intervention and 
outcomes in future research would allow meta-analysis.  
Multi-disciplinary palliative care is effective in people with symptomatic heart 
failure: a systematic review and narrative synthesis
Datla, Sushma; Verberkt, Cornelia Antonia; Hoye, Angela; Janssen, Daisy; Johnson, Miriam J
This is the accepted manuscript of an article published in Palliative medicine, the version of record 
can be accessed at https://journals.sagepub.com/doi/10.1177/0269216319859148
Page 3 of 36 
KEYWORDS: heart failure; palliative care; hospice; systematic review; quality of life 
KEY STATEMENTS 
What is already known about the topic? 
People with advanced heart failure have poorer access to palliative care than people with 
cancer and the evidence base in support of heart failure palliative care is less developed. 
What this paper adds 
We have drawn together the current literature, both observational and experimental, 
investigating the use of palliative care in people with symptomatic heart failure. 
Implications for practice, theory or policy 
Our findings support the use of multi-disciplinary palliative care in this patient group, as 
distinct from single components only, but trials do not identify who would benefit most from 
specialist palliative referral. There are no sufficiently robust multi-centre evaluation phase 
trials to provide generalisable findings. 
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INTRODUCTION 
The great advances in the management of heart failure(1) brings, as a consequence, more 
people living to experience advanced disease (New York Heart Association class III and 
IV)(2) where response to medical or device therapy is limited.(3) People with end-stage 
disease can have severe symptom burden, poor quality of life,(4) and social isolation. As 
prognostication is difficult,(5, 6) patients may receive invasive yet futile treatment in hospital 
during the last days of life, adding to stress for patients, families and the limited healthcare 
resources.(7) 
Palliative care is a multi-disciplinary approach to care for people with life-limiting, 
progressive illness, aiming to maximise quality of life until death, and provide family support 
through to bereavement.(8) Evidence supports palliative care integrated into management of 
people with cancer,(9) and other chronic conditions.(10) Benefits include improved symptom 
burden and quality of life, decreased healthcare utilisation and costs,(11) autonomy in care at 
the end of life, and patient satisfaction.(12) Access to palliative care services alongside 
cardiac care for patients with advanced HF is recommended(13-15) but this is not reflected 
routinely in practice. Fewer people with HF are placed on the primary care palliative register 
in the United Kingdom than those with cancer (7% vs 48%),(16) and a similar proportion 
with advanced heart failure are referred for palliative care during hospital admissions.(17) 
Barriers to palliative care access include the unpredictable course of heart failure and a 
conflation of “palliative” and “dying” in the minds of clinicians, patients, and the public.(14, 
18) Despite the well-established role of palliative care in other areas, this is not so for people 
with advanced heart failure, for whom heart failure management has one of the strongest 
evidence bases for any condition; this is likely to be an additional significant barrier in a 
specialty used to large trials which underpin practice. 
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The aim of this systematic review is to identify and analyse current available evidence which 
addresses the question of whether palliative care in people with advanced heart failure, is 
effective with regard to, patient-reported outcomes (symptom burden, depression, functional 
status, quality of life), resource use and costs of cares. The findings are discussed in the 
context of implications for clinical practice and gaps in knowledge are highlighted to help 
target future research. 
 
METHODS 
We conducted a systematic literature review and narrative synthesis. The protocol was 
registered on PROSPERO (ID=CRD42016029911) and Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The search 
was updated to March 31st 2019 using a rapid methodology (single reviewer, simplified 
search terms, one database [Medline]). The methods otherwise describe the original search. 
Search strategy 
Medline, Cochrane database, CINAHL, PsycINFO, HMIC, and Care Search Grey Literature 
were searched using free text and MeSH terms from 1995 to 2017 inclusive. The search 
strings represented the terms to identify the population (symptomatic heart failure) and the 
intervention of interest (palliative care) [supplementary table 1]. This was intentionally broad 
given the nature of the interventions sought. Reference lists and citations of included studies 
and key review articles were searched. Experts in the field were contacted. There were no 
language restrictions.   
Eligibility criteria  
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Types of participants: Studies were included if participants had symptomatic heart failure 
(New York Heart Association class III & IV) or other evidence of advanced disease such as 
left ventricular ejection fraction <40%. Where only a subset were participants with 
symptomatic heart failure, studies were included if outcome data could be extracted for this 
subset.  
Types of interventions: Any study with a palliative care, or component(s) of, intervention 
delivered by specialist or generalist services was included apart from advance care planning 
alone. Specialist palliative care services are those where palliative care is the core business 
and staff have additional specialist training. Generalist services refer to all other services 
where basic palliative care may be provided, but palliative care is not their primary purpose, 
such as primary care or hospital services such as cardiology. For this review, cardiac 
rehabilitation interventions are considered as “rehabilitative” rather than “palliative” services 
and were thus excluded.   
Types of comparator: There was no restriction on the comparator arm or care setting.  
Types of study design: Experimental or quasi-experimental, observational, and service 
evaluations, and national audits were included. Studies with unclear methods, duplicate 
publications (except where discreet outcomes were presented), opinion pieces, narrative 
reviews, editorials, case histories or case series were excluded. 
Study selection 
One reviewer (SD) screened all titles and abstracts against the eligibility criteria and a second 
reviewer (CV) independently reviewed a proportion (18%) and both screened retrieved full 
papers. Any disagreements were resolved by discussion between the two reviewers with 
access to a third reviewer (MJJ) where necessary. 
Data extraction 
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A data extraction spreadsheet was designed and piloted. Two researchers (SD, CV) 
independently extracted the data. Disagreements or discrepancies were resolved by mutual 
consent or by involvement of a third author (MJJ). Study identifiers, study characteristics, 
information regarding the population, intervention, comparators, and outcomes, including 
results were extracted. 
Where data was unreported or ambiguous, attempts were made to contact the authors of the 
paper.  
Risk of bias assessment 
SD and CV independently assessed the risk of bias and the disagreements were resolved by 
discussion and access to MJJ as needed. Randomised controlled trials were assessed with the 
use of the Cochrane Risk of Bias Tool and the Newcastle-Ottawa quality assessment Scale 
was used to judge the risk of bias in cohort and case control studies. 
Synthesis of results 
Descriptive narrative synthesis of the study design, the included population, the intervention, 
and comparator are presented in tabular format.  
For the purpose of the review, randomised controlled trials, in accordance with the Medical 
Research Committee Framework for complex intervention development,(19) the terms 
“phase II/III” were not used. Trials were identified as feasibility and pilot phase trials and 
evaluation trials on the following basis. Studies with a stated aim to assess the efficacy or 
effectiveness of the intervention were classed as evaluation phase randomised controlled 
trials. Additionally, studies with power calculations aiming to design adequately powered 
trials to identify the effect of the intervention were also categorised as evaluation phase 
randomised controlled trials.  
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Outcomes and results were described; however, a meta-analysis was not conducted due to 
heterogeneity of outcomes, populations, and interventions. 
RESULTS 
The search process for the included studies is summarised in a flow chart (figure 1). The 
original database search identified 7,934 records after de-duplication, and a further 85 in the 
rapid update review. Overall, twenty-three studies met the inclusion criteria.
Figure 1: PRISMA flowchart depicting the search process and the study selection 
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Study characteristics 
Study design and setting 
Eight papers reporting seven evaluation phase randomised controlled trials,(20-27) four 
feasibility and pilot phase studies/randomised controlled trials,(28, 29, 30, 31) one quasi-
experimental study,(32) seven cohort studies,(33-39) two case-control studies,(40, 41) and 
one cross-sectional study(42) were included. The characteristics of included studies are 
summarised in table 1 (interventional studies) and table 2 (observational studies). Further 
details including outcomes and results are available in supplementary table 2. Sixteen studies 
were community-based,(21, 22, 25, 27-29, 35-42) two extended across community and 
hospitals,(21, 25) three were set in the hospital alone(24, 27, 32) and two in hospice.(33, 42) 
Sample sizes ranged from 13(28) to 16,613.(42) Six studies(20-24, 26) provided sample 
size/power calculations. Bekelman et al.,(21) Brännström et al.,(22) and Hopp et al.(23) 
achieved adequate power to detect statistically significant differences in outcomes (90%, 
80%, and 80% respectively). Aiken et al.,(20) Rogers et al.,(24) and Sidebottom et al.(26) 
were designed to reach adequate power however, due to difficulty in recruitment and high 
attrition rate, partly due to death, these studies did not reach their proposed sample size. 
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Table 1: Characteristics of included interventional studies 
First author, 
year and 
country 
Study setting 
Participants: sample size (n), age (years), sex (%), disease characteristics 
(NYHA, LVEF) 
Intervention Comparator 
Intervention Comparator 
Evaluation phase RCTs 
Aiken LS (20) 
2006 
USA 
Community based 
and  hospital based 
N = 100 (CHF = 67) 
Mean Age (SD) = 68 (14) 
Sex: M = 42.0; F = 58.0 
N = 90 (CHF = 62) 
Mean Age (SD) = 68 (14) 
Sex: M = 30.0; F = 70.0 
PhoenixCare: Home-based 
palliative care 
Usual care 
Bekelman DB 
(21) 
2015 
USA 
Community based 
with outpatient 
consultations 
N = 187 
Mean Age (SD) = 68.3 (9.6) 
Sex: M = 95.2; F = 4.8 
NYHA: class I = 16 (8.9%) 
class II = 77 (42.8%) 
N = 197 
Mean Age (SD) = 67.9 (10.6) 
Sex: M = 98.0; F = 2.0 
NYHA: class I = 16 (8.5%) 
class II = 85 (45.0%) 
Patient-centred disease 
management 
Regular care 
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class III = 82 (45.6%) 
class IV = 5 (2.8%) 
LVEF: Normal = 78 (45.6%) 
Mild = 34 (19.9%) 
Moderate = 46 (26.9%) 
Severe = 13 (7.6%) 
class III = 82 (43.4%) 
class IV = 6 (3.2%) 
LVEF: Normal = 84 (47.5%) 
Mild = 34 (19.2%) 
Moderate = 32 (18.1%) 
Severe = 27 (15.3%) 
Brännström M 
(22) 
2014 
Sweden 
Community based 
with outpatient 
consultations 
N = 36 
Mean Age (SD) = 81.9 (7.2) 
Sex: M = 72.2; F = 27.8 
NYHA: class III = 28 (77.8%) 
class IV = 8 (22.2%) 
LVEF: 40-49% = 13 (36.1%) 
30-39% = 16 (44.4%) 
N = 36 
Mean Age (SD) = 76.6 (10.2) 
Sex: M = 69.4; F = 30.6 
NYHA: class III = 23 (63.9%) 
class IV = 11 (30.6%) 
LVEF: 40-49% = 12 (33.3%) 
30-39% = 21 (58.3%) 
PREFER: Palliative advanced 
home care and heart failure care 
No information 
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<30% = 7 (19.4%) <30% = 3 (8.3%) 
Hopp FP (23) 
2016 
USA 
Hospital based 
N = 43 
Mean Age (SD) = 67.0 (11.0) 
Sex: M = 60.5; F = 39.5 
Mean LVEF = 36.4% (16.7) 
N = 42 
Mean Age (SD) = 68.0 (13.0) 
Sex: M = 42.9; F = 57.1 
Mean LVEF = 38.1% (16.8) 
Palliative care consultation No information 
Rogers JG (24) 
2017 
USA 
Community based 
and  hospital based 
N = 75 
Mean Age (SD) = 71.9 (12.4) 
Sex: M = 56.0; F = 44.0 
NYHA: class III = 54 (72.0%) 
class IV = 15 (20.0%) 
LVEF: >55% = 21 (28.0%) 
40-55% = 14 (18.7%) 
25-40% = 17 (22.7%) 
N = 75 
Mean Age (SD) = 69.8 (13.4) 
Sex: M = 49.3; F = 50.7 
NYHA: class III = 58 (77.3%) 
class IV = 5 (6.7%) 
LVEF: >55% = 14 (18.7%) 
40-55% = 19 (25.3%) 
25-40% = 14 (18.7%) 
PAL-HF: Multi-component 
palliative care 
Usual care 
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<25 = 23 (30.7%) <25 = 28 (37.3%) 
Sahlen KG (25); 2015; Sweden: Details are the same as Brännström et al. (23) 
Sidebottom 
AC (26) 
2015 
USA 
Inpatient 
consultation 
N = 116 
Mean Age (SD) = 76.0 (11.9) 
Sex: M = 47.4; F = 52.6 
N = 116 
Mean Age (SD) = 70.9 (13.6) 
Sex: M = 57.8; F = 42.2 
Palliative care consultation No information 
Wong FKY 
(27) 
2016 
China 
Community based 
N = 43 
Mean Age (SD) = 78.3 (16.8) 
Sex: M = 43.9; F = 56.1 
NYHA: class II = 6 (14.0%) 
class III = 31 (72.0%) 
class IV = 6 (14.0%) 
Mean LVEF = 39.0% (14.0) 
N = 41 
Mean Age (SD) = 78.4 (10.0) 
Sex: M = 61.0; F = 39.0 
NYHA: class II = 3 (7.3%) 
class III = 22 (53.7%) 
class IV = 16 (39.0%) 
Mean LVEF = 37.0% (17.0) 
Transitional palliative care  Usual care 
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Feasibility and pilot phase RCTs 
Paes P (28) 
2005 
UK 
Outpatient 
consultations 
N = 6 
Mean Age (SD) = 73.2 (4.2) 
Sex: M = 100.0; F = 0.0 
NYHA: class III = 3 (50.0%) 
class IV = 3 (50%) 
N = 7 
Mean Age (SD) = 78.0 (7.0) 
Sex: M = 80.0; F = 20.0 
NYHA: class III = 3 (60.0%) 
class IV = 2 (40%) 
Palliative care consultation Regular care 
Bakitas M (29) 
2017 
USA 
Community based 
with outpatient 
consultations 
N = 61 
Mean Age (SD) = 70.59 (10.7) 
Sex: M = 50.8; F = 49.2 
NYHA: class I = 1 (1.6%) 
class II = 3 (4.9%) 
class III = 43 (70.5%) 
class IV = 12 (19.7%) 
Single-arm study 
ENABLE CHF-PC: Early palliative care intervention 
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Unknown = 2 (3.3%) 
Mean LVEF = 37.86% (16.3) 
O’Donnell A 
(30) 
USA 
In-patient and/or 
recent discharged to 
community from 
admission for acute 
decompensated heart 
failure 
N = 26 
Mean Age (SD) = 74.7 (11.2) 
Sex: M 53.9, F = 46.1 
NYHA class 1 or 2 = 10 (38.5%) 
NYHA class 3 or 4 = 16 (61.5%) 
Mean LVEF = 30% (14) 
N = 24 
Mean Age (SD) = 69.2 (10.2) 
Sex: M = 62.5, F = 37.5  
NYHA class 1 or 2 = 8 (33.3%) 
NYHA class 3 or 4 = 16 (66.7%) 
Mean LVEF = 36% (17) 
Social worker consultation for 
care planning 
Palliative care physician 
consultation 
Usual care and 
printed materials 
about palliative 
care and advance 
care planning 
Johnson MJ 
(31) 
UK 
Community based 
with out-patient 
consultations 
Cohort 1: palliative cardiology 
N = 43 
Mean Age (SD) = 75.8 (12.3) 
Sex: M 55.8, F = 44.2 
NYHA: class I = 0 
Cohort 2: usual care 
N = 34 
Mean Age (SD) = 78.4 (11.3) 
Sex: M 50.0, F = 50.0 
NYHA: class I = 0 
Cohort 1: palliative care clinic 
conducted by consultant 
cardiologist with special 
interest, and heart failure nurse 
consultant 
Cohort 2: usual 
care 
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class II = 0 
class III = 40 (93.0) 
class IV = 3 (7.0) 
class II = 3 (8.8) 
class III = 30 (88.2) 
class IV = 1 (2.9) 
Quasi-experimental study 
Tadwalkar R 
(32) 
2014 
USA 
Inpatient visits 
N = 14 
Mean Age (SD) = 58 (11) 
Sex: M = 42.9; F = 57.1 
N = 9 
Mean Age (SD) = 57 (10) 
Sex: M = 55.6; F = 44.4 
Religious support 
Non-religious 
support 
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Table 2: Characteristics of included observational studies 
First author, 
year and 
country 
Study setting 
Participants: sample size (n), age (years), sex (%), disease 
characteristics (NYHA, LVEF) 
Intervention Comparator 
Intervention Comparator 
Cohort studies 
Connor SR (33) 
2007 
USA 
Hospice care 
(Retrospective) 
N = 2095 (CHF = 83) 
Mean Age = 73.5 
Sex: M = 55; F = 45 
N = 2260 (CHF = 457) 
Mean Age = 73.9 
Sex: M = 59; F = 41 
Hospice care 
No claims for 
hospice care 
Enguidanos SM 
(34) 
2005 
USA 
Community based with 
outpatient 
consultations 
(Prospective) 
N = 159 (CHF = 31) 
Mean Age (SD) = 70 (13.92) 
Sex: M = 49.1; F = 50.9 
N = 139 (CHF = 51) 
Mean Age (SD) = 73 (13.29) 
Sex: M = 44.6; F = 55.4 
Home-based palliative care 
program 
Standard health care 
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Pattenden JF 
(35) 
2013 
UK 
Community based 
(Prospective) 
N = 99 
Mean Age (SD) = 81.7 
Sex: M = 60.6; F = 39.4 
N = 98 
Mean Age (SD) = 78.85 
Sex: M = 62.0; F = 37.8 
“Better Together” intervention: 
education and palliative nursing 
'Convenience sample' 
- historical 
Evangelista LS 
(36)  
2014 
USA 
Outpatient 
consultations 
(Prospective) 
N = 29 
Mean Age (SD) = 53.3 (7.3) 
Sex: M = 75.9; F = 24.1 
NYHA: class II = 20 (69.0%) 
class III = 9 (31.0%) 
Mean LVEF = 23.1% (4.3) 
N = 13 
Mean Age (SD) = 52.5 (7.6) 
Sex: M = 61.5; F = 38.5 
NYHA: class II = 9 (69.2%) 
class III = 4 (30.8%) 
Mean LVEF = 30.5% (9.7) 
Single arm study 
Palliative care consultations: 
'Intervention group' 
Participants receiving > 2 palliative care consultations 
'Comparator group' 
Participants receiving ≤ 1 palliative care consultations 
Evangelista LS 
(37) 
2014 
Outpatient 
consultations 
(Prospective) 
N = 29 
Mean Age (SD) = 54.1 (8.4) 
Sex: M = 75.9; F = 24.1 
N = 7 
Mean Age (SD) = 52.7 (6.3) 
Sex: M = 57.1; F = 42.9 
Single arm study 
Palliative care consultations: 
'Intervention group' 
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USA NYHA: class II = 20 (69.0%) 
class III = 9 (31.0%) 
Mean LVEF = 25.9% (5.3) 
NYHA: class II = 5 (71.4%) 
class III = 2 (28.6%) 
Mean LVEF = 23.1% (4.3) 
Participants receiving palliative care consultation and 
follow up. 
'Comparator group' 
Participants receiving initial palliative care consultation 
only. 
Taylor GJ (38) 
2017 
USA 
Community based 
(Retrospective) 
N = 32 
Age Range (Median) = 48-94 (70) 
Sex: M = 100; F = 0 
NYHA: class III = 2 (6.7%) 
class IV = 28 (93.3%) 
23 patients had HFrEF (LVEF <30%); 7 had HFpEF. 
Single arm study 
Home delivered palliative care 
Wong RC (39) 
2013 
Community based 
(Prospective) 
N = 44 
Mean Age (SD) = 79 (9) 
Single arm study 
Home palliative care program 
Page 20 of 36 
 
Singapore Sex: M = 38.6; F = 61.4 
NYHA: class III = 31 (70.0%) 
class IV = 13 (30.0%) 
Case-control studies 
Cassel JB (40) 
2016 
USA 
Community based 
(Retrospective) 
N = 174 
Mean Age (SD) = 87.5 (6.6) 
Sex: M = 44.3; F = 55.7 
N = 499 
Mean Age (SD) = 87.1 (6.4) 
Sex: M = 43.7; F = 56.3 
Transitions: 
Concurrent medical and palliative 
care  
No information 
Evangelista LS 
(41) 
2012 
USA 
Outpatient consultation 
(Prospective) 
N = 36 
Mean Age (SD) = 53.9 (8.0) 
Sex: M = 72.2; F = 27.8 
NYHA: class II = 25 (69.4%) 
class III = 11 (30.6%) 
Mean LVEF = 25.4% (5.2) 
N = 36  
Mean Age (SD) = 53.3 (8.7) 
Sex: M = 69.4; F = 30.6 
NYHA: class II = 26 (72.2%) 
class III = 10 (27.8%) 
Mean LVEF = 26.0% (6.2) 
Palliative care consultation No information 
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Cross-sectional study 
Blecker S (42) 
2011 
USA 
Hospice care 
N = 6,436 
Mean Age (SD) = 85.0 (7.6) 
Sex: M = 39.5; F = 60.5 
N = 10,177 
Mean Age (SD) = 83.6 (7.9) 
Sex: M = 44.5; F = 55.5 
Hospice care 
No claims for 
hospice care 
Abbreviations: NYHA = New York Heart Association; LVEF = left ventricular ejection fraction; RCT = randomised controlled trial; CHF = 
congestive heart failure; SD = standard deviation; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced 
ejection fraction  
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Participants 
Across 23 studies, 19,891 participants (average age range 52.5 to 87.5; men = 59.3%) were 
included. Severity of heart failure was indicated by New York Heart Association 
classification(21, 22, 24, 27, 28, 30, 31, 36-39, 41)  (figure 2), Kansas City Cardiomyopathy 
Questionnaire,(21, 30, 31) recent acute episode resulting in visits to the emergency 
department, hospitalisation or symptoms of end of life.(20, 22-25, 27, 30, 31, 34, 35, 38) In 
four studies,(21, 22, 24, 38) the data on left ventricular ejection fraction were presented in 
categories – 'normal' (34.6%), 'mild' (19.7%), 'moderate' (24.7%) and 'severe' (21.0%) left 
ventricular ejection fraction. The average left ventricular ejection fraction of the patients 
included in seven other studies(23, 27, 29 -31, 36, 37, 41) was 32%. 
 
Figure 2: Distribution of participants across the NYHA classes reported in 13 studies; reported here for 
the 12 studies where all four classes are reported separately 
Intervention 
The intervention varied in terms of components and delivery (supplementary table 3) and 
details were missing in Connor et al.(33) and Blecker et al.(42) Most common aspects of 
palliative care included were symptom management, psychological support and advance care 
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planning. All studies included an assessment of current medical status and patients' needs, 
and were provided by a multidisciplinary team. 
Comparator 
In general description of the comparator was absent(22, 23, 25, 26, 30, 33, 35, 39-42) or 
minimal(20, 21, 24, 27, 28, 34). Six of the included studies were single arm studies, with no 
comparator.(29, 32, 36-39) One feasibility study reported two cohorts,(31) one from a 
palliative cardiology clinic, and one from usual care, but the study was not designed as quasi-
experimental although descriptive comparisons were made. This study is reported as a 
feasibility study, but as the methods fit best with observational design, the quality was 
assessed as a cohort study. 
Risk of bias 
Evaluation phase studies 
The risk of bias of the evaluation phase studies is summarised in supplementary table 4 using 
the Cochrane Risk of Bias tool. The main source of bias was the lack of blinding, but this was 
inherently impossible. Three trials attempted to blind outcome assessors.(20, 21, 27) There 
were a number of other issues relating to risk of bias. Missing data, particularly of patient-
reported primary outcomes was significant, but details on pattern of missingness or how this 
was handled were not provided apart from Rogers et al.(24) (used a mixed effects model for 
the primary outcomes). Wong et al.(27) used the generalised estimating equation which is 
able to take missing data into account, but this was not made explicit as a method of handling 
missing data.(20, 28) Other biases include the risk of type 1 errors due to multiple statistical 
testing on small participant samples,(20) statistically significant differences in New York 
Heart Association classes between arms at baseline,(27) and poor fidelity to allocated arms 
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with some participants accessing palliative care as part of usual care in the comparator 
arms.(24, 26) 
Observational studies – cohort studies 
The Newcastle-Ottawa Scale risk of bias assessment for the seven cohort studies is 
summarised in supplementary table 5. The four single-arm cohort studies could not be 
assessed fully as there is no non-exposed group. Most cohort studies had representative 
samples, however, Taylor et al.(38) recruited male veterans only and the second cohort in 
Johnson et al used a convenience sample only.(31) None of the included studies measured the 
outcome of interest at baseline, but these were expected to improve or worsen based on 
exposure rather than appear or disappear. Comparability could be assessed through the 
baseline characteristics of the included participants, but analyses did not control for 
confounding factors. The primary objective for Johnson et al was to test the feasibility of a 
subsequent trial with regard to recruitment, attrition and data quality from these two settings, 
and was not designed to compare the two groups in any way other than descriptively.(31) 
Observational studies – case-control studies 
The Newcastle-Ottawa Scale risk of bias assessment for the two case-control studies is 
summarised in supplementary table 6. The case definition, case representativeness, and 
selection of controls was appropriate in both studies, however the controls are poorly defined. 
The comparison groups were matched for age, sex, and race. Evangelista et al.(41) provided 
no information on how the exposure was measured and neither study provided information on 
non-response rates. 
Observational studies – Cross-sectional study 
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Cross-sectional design has inherent flaws, e.g. the exposure and outcome are measured at the 
same time-period. The summary quality rating for Blecker et al.(42) is fair, but the sample is 
not justified, no weight is given to level of exposure to intervention or repeat exposure in the 
analysis and the outcome measurement relied significantly on coding.  
Outcomes 
The salient results of the outcomes from the included studies are summarised in table 3. 
Patient-centred outcomes 
Symptom burden was measured with the use of Edmonton Symptom Assessment Scale(22, 
26, 27, 31, 36, 37, 41) and Memorial Symptom Assessment Scale.(20, 29, 32) Five(26, 29, 
36, 37, 41) out of the nine studies investigating the change in symptom burden found 
significant improvement in symptoms such as breathlessness, pain and fatigue. Participants in 
the intervention arm of Aiken et al.(20) experienced significantly higher symptom distress 
than their counter-parts in the control arm, and in Johnson et al, symptoms improved more in 
the usual care cohort.(31) Nine studies investigated depression using the Patient Health 
Questionnaire-9,(21, 26, 30,  41) Hospital Anxiety and Depression Scale,(24, 25, 29, 31) and 
Quick Inventory of Depressive Symptomatology.(32) Five studies(21, 24, 25, 30, 41) found 
significant improvement in depression with the intervention. There was a significant 
improvement in New York Heart Association classes from baseline following the 
intervention,(22, 38) but  no change in functional status measured by Palliative Performance 
Scale(27) or Australian-modified Karnofsky Performance Scale.(31)  
Various measures were used to assess quality of life, including, Kansas City Cardiomyopathy 
Questionnaire and EuroQol-5D. Some studies used a combination to assess disease- or 
intervention-specific and health-related quality of life. Seven(24-27, 29, 30, 41) out of 11 
Page 26 of 36 
 
studies found significant improvement in quality of life, with one other(22) noting a 
significant improvement in health-related quality of life but not in disease-specific quality of 
life. Five studies investigated the effect on survival, while others(20, 24, 27, 29, 30, 31) 
commented on attrition due to death. Four studies(22, 23, 26, 31) found no significant 
difference in mortality between the intervention and comparator arm. There were 
significantly fewer deaths in the intervention arm in Bekelman et al.(21) and the participants 
survived significantly longer in Connor et al.(33) 
Resource use 
Thirteen studies evaluated use of resources in different ways. Seven(22, 27, 31, 35, 39, 40, 
42) out of ten studies found significant reduction in hospitalisations and re-admissions, and 
five(29, 31, 34, 40, 42) out of six studies had significant reduction in length of stay in 
hospital or service use. There was no significant difference in hospice use among the 
participants. Patients in the intervention arm were more likely to complete advance care 
planning(26, 30, 31) and less likely to die in hospital.(34, 40) Three studies(34, 35, 40) found 
a statistically significant drop in costs in the intervention arm, one feasibility study found 
preliminary cost savings in the intervention group (31), however one found no significant 
difference and the expenditure of the intervention arm in Blecker et al.(42) was significantly 
higher when adjusted for covariates. 
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Table 3: Summary of salient outcome results 
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Aiken LS (20)           
Bekelman DB (21)           
Brännström M (22)           
Hopp FP (23)           
Rogers JG (24)           
Sahlen KG (25)           
Sidebottom AC (26)           
Wong FKY (27)           
Paes P (28)           
Bakitas M (29)           
Tadwalkar R (32)           
O’Donnell A (30)           
Johnson MJ (31)           
Connor SR (33)           
Enguidanos SM (34)           
Pattenden JF (35)           
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Study 
Patient-centred outcomes Resource use 
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Evangelista LS† (36)           
Evangelista LS* (37)           
Taylor GJ (38)           
Wong RC (39)           
Cassel JB (40)           
Evangelista LS (41)           
Blecker S (42)           
Note that the quality of life assessment was conducted separately in some studies for 
disease-specific/ health-related/ palliative care-specific data therefore may have multiple 
entries. 
ACP = Advance care planning 
Key:  = results significantly in favour of intervention,  = results significantly in favour of 
control,  = no significant difference 
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DISCUSSION 
This review collated the current body of evidence from a range of countries examining the 
effects of palliative care on patients with advanced heart failure with the intent to guide future 
clinical and research priorities for this population. 
The results from evaluation phase studies support the use of multi-component, multi-
disciplinary palliative care interventions. Benefits were improvement in patient-centred 
outcomes including symptom burden, depression, quality of life, functional status, and 
reduced use of healthcare resources and costs of care. 
Findings were inconsistent across all studies, likely due to the significant clinical and 
methodological heterogeneity between studies, across all aspects: study design, study 
population and setting, components of the intervention and control and choice of outcome 
measures. 
Limitations of the included studies 
Although we searched the international literature, 16/23 studies were conducted in the United 
States which may limit generalisability. 
Patients in randomised controlled trials were randomised individually and intervention was 
delivered in the same site as the control arm; therefore, there is a risk of control group 
contamination.(20, 21, 26, 30, 41) Also, some patients did not receive the prescribed 
intervention either due to limited availability of providers(26) or limited access to care if 
patients deteriorated rapidly.(35) Meanwhile, other patients received palliative care despite 
allocation to control in response to clinical need.(24, 26) Therefore, the effect of the 
intervention may be under-estimated. Further, in one study (20) heart failure participants 
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were a subgroup only. Baseline differences in symptom distress (higher in the intervention 
group) were therefore not adjusted for, which may have affected the findings.  
Conclusions from the non-randomised trials(32) and observational studies regarding the 
precise impact of the intervention, should be cautious due to risk of selection bias and effect 
of confounders which were either not reported, or, if they were, adjusted findings were not 
presented.  
Eleven studies(20-25, 27-28, 32, 35, 39) included only patients with New York Heart 
Association class III and IV, consistent with the population most likely to benefit from 
palliative care. Other studies did not provide New York Heart Association classification or 
also included patients with New York Heart Association class I and II but without subgroup-
analysis. This may have led to an underestimation of effect. 
Palliative care is a multi-component intervention, but was variably delivered across included 
studies. Studies investigating the effects of limited aspects of palliative care (32) (23) found 
no significant difference in outcomes between the intervention and the comparator, unlike 
studies investigating a more comprehensive intervention. Two studies(26, 41) assessed the 
effect of a single palliative care consultation – which does not represent usual palliative care 
practice. Hopp et al.(324) chose completed “do not resuscitate” orders as the primary 
outcome which is inconsistent with the defined aim of palliative care (improvement in quality 
of life and symptom control).(8)   
Apart from the risk of contamination, the quality of the studies designed to evaluate 
effectiveness(20-27) was good, accepting that blinding was not possible. However, as 
expected with palliative care studies, there were missing data in patient-report primary 
outcomes at levels associated with bias. Rogers et al.(24) addressed this explicitly for their 
primary outcomes using a linear mixed models with an indicator variable for the treatment 
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group and Wong et al.(27) used generalized estimating equations. As with previously noted 
poor reporting of missing data,(43) neither described the pattern of missingness to confirm 
that this approach was appropriate.(44) However, Rogers et al.(24) did note the significant 
levels of missing data and made the reasonable comment that bias should be limited because 
the attrition was similar in both arms.  
Strengths and limitations of the review 
This review was not restricted to randomised controlled trials, to allow an understanding of 
the breadth and gaps in the published literature relating to palliative care for people with heart 
failure. However, as with any systematic review, some studies with potential for inclusion 
may have been missed. Due to the clinical and methodological heterogeneity between the 
included studies, we were unable to conduct a meta-analysis. This heterogeneity reflects the 
variation in palliative care implementation around the world.  
Implications for clinical practice and research 
Palliative care delivered as comprehensive intervention with regular assessments of patients' 
needs and a tailored management appears to be beneficial for patients with symptomatic heart 
failure. However, in practice, referral of all patients with New York Heart Association III and 
IV heart failure to specialist palliative care seems both unnecessary and unsustainable. 
Current recommendations(13, 14, 15, 5) support an integrated approach where usual care 
teams (in cardiology, elderly care or primary care) provide general palliative care for 
identified needs but involve specialist palliative care for complex or persistent concerns.(46) 
Although the study of a palliative care intervention led by the cardiology team was not 
designed to show effectiveness,(31) it demonstrates that it is possible to deliver in clinical 
practice.  
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Future trials of specialist palliative care should focus on the patients with heart failure most 
likely to benefit from specialist intervention. A recent cohort study of people admitted to 
hospital for heart failure identified that those most likely to have specialist palliative care 
needs (defined as those with “persistently severe impairment of any patient reported 
outcome”)  as those with a Kansas City Cardiomyopathy Questionnaire summary score of 
<29 on admission.(47) This moves away from the question of “when is the right time to 
refer”, which assumes proximity to death as the primary criterion.  
Well-designed studies which minimise contamination (for example, cluster design) are also 
needed to test the effectiveness and cost-effectiveness of interventions whereby the usual care 
team provide most palliative care, supported by specialists as needed. Consensus around core 
components of palliative care, configuration of palliative care teams, the most effective 
model of service provision to ensure tailored generalist and/or specialist palliative care, core 
outcome sets and careful thought and agreement about how to both minimise and manage 
missing data would facilitate both quality of results and the ability to conduct meta-analysis. 
Conclusions 
Multi-component, multi-disciplinary palliative care interventions appear to provide patient-
centred benefit and reduce use of healthcare resources and costs. However, there are no 
sufficiently robust multi-centre evaluation phase trials to provide generalizable findings. 
Consensus is needed for regarding core intervention components, study population, outcome 
sets, management strategies for missing data and optimum design to inform multi-centre 
trials for use in future meta-analysis. 
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